Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.49 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076305 | 0.89 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4080438 | 0.89 | CNR1 (1.00) | CNR1SMN1; SMN2MEN1S1PR1KMT2A | |
| SCHEMBL8230447 | 0.81 | CNR1 (0.75) | CNR1NPC1RAB9A | |
| SCHEMBL1315954 | 0.80 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4079877 | 0.79 | CNR1 (0.67) | CNR1NPC1RAB9APOLB | |
| SCHEMBL675796 | 0.79 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4087802 | 0.79 | CNR1 (0.82) | CNR1KMT2A | |
| SCHEMBL674885 | 0.79 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4080151 | 0.77 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4080443 | 0.75 | CNR1 (1.00) | CNR1NPC1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084127-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008059335-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | claimed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | claimed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | claimed |
| EP-2321351-B1 | ANTIBODIES TO CCR2 | PFIZER (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9238691-B2 | Nucleic acids encoding antibodies to CCR2 | PFIZER INC. (US) | 2016-01-19 | — | — | US | disclosed |
| CN-102239180-B | Antibodies to CCR2 | PFIZER | 2014-12-31 | — | — | CN | disclosed |
| US-20140342450-A1 | ANTIBODIES TO CCR2 | AMGEN FREMONT INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8710191-B2 | Antibodies to CCR2 | PFIZER INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | FONG TUNG M (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1482794-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003075660-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | MERCK & CO., INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | CNR1 13/4885NPC1 2827/4885RAB9A 1861/4885 |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | CNR1 1/4885NPC1 767/4885RAB9A 1785/4885 |
| US-20140342450-A1 | ANTIBODIES TO CCR2 | CCR2, CCR1, CCR5 | CNR1 1110/4885NPC1 2695/4885RAB9A 4701/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | CNR1 1/4885NPC1 767/4885RAB9A 1785/4885 |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | CNR1, HSD11B1, HSD17B1 | CNR1 1/4885NPC1 242/4885RAB9A 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.